Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.5337 | 1 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.5337 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0693 | 0 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.5337 | 1 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0798 | 0.0225 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.5337 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.5337 | 1 | 0.5 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0798 | 0.0225 | 0.5 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0798 | 0.0225 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0693 | 0 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.5337 | 1 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.5337 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0693 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0693 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0693 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 25 uM | Inhibition of mouse COX-2 assessed as inhibition of [14C]arachidonic acid to radiolabeled prostaglandins preincubated for 15 mins by TLC-based assay | ChEMBL. | 25408841 |
IC50 (binding) | > 25 uM | Inhibition of ovine COX-1 assessed as inhibition of [14C]arachidonic acid to radiolabeled prostaglandins preincubated for 15 mins by TLC-based assay | ChEMBL. | 25408841 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.